FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

Article

The use of belzutifan has been approved by the FDA for patients with cancer that is associated with von Hippel-Lindau disease who do not need immediate surgery.

The FDA has approved the use of belzutifan (MK-6482) for cancers associated with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNETs) that do not need immediate surgery, according to a press release from the FDA.1

Thus far, patients with VHL-associated RCC experienced an overall response rate (ORR) of 49% (95% CI, 36%-62%). All patients who experienced a response were monitored for a minimum of 18 months from the start of their treatment with belzutifan. Although the median duration of response (DOR) was not reached, 56% of responders had a DOR of 12 months or more, as well as a median time to relapse of 8 months. Additionally, patients with measurable CNS tumors (n = 24) had an ORR of 63% and the pNET cohort (n = 12) had an ORR of 83%. Similarly, the median DOR was not reached and 73% and 50% of both groups, respectively, had a response lasting 12 months or more.

The agent is currently under investigation as part of the ongoing open-label Study 004 (NCT03401788), which enrolled 61 patients with VHL-associated RCC, as well as enrolling patients with other VHL tumors, including CNS and pNET. Patients received 120 mg of belzutifan once daily until experiencing disease progression or unacceptable toxicity.

The most common adverse effects in patients who were treated with the hypoxia-inducible factor inhibitor included decreased hemoglobin, anemia, fatigue, increased creatinine, headache, and dizziness. Notably, anemia and hypoxia associated with treatment with belzutifan can be severe. Seven percent of patients developed grade 3 anemia. Additionally, the use of erythropoiesis stimulating agents to treat anemia in patients who have been treated with belzutifan is not recommended.

Reference

FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. News release. FDA. August 13, 2021. Accessed August 13, 2021. https://bit.ly/37DMnzV

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.